Small intestine adenocarcinoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:42 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Small intestine adenocarcinoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness of Fluorouracil, Levoleucovorin, and Oxaliplatin in Patients with Resected Small Bowel Adenocarcinoma https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-fluorouracil-levoleucovorin-and-oxaliplatin-in-patients-with-resected-small-bowel-adenocarcinoma/ Wed, 29 Apr 2026 14:57:31 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-fluorouracil-levoleucovorin-and-oxaliplatin-in-patients-with-resected-small-bowel-adenocarcinoma/ This clinical trial is focused on studying the effects of adjuvant chemotherapy for patients with small bowel adenocarcinoma, a type of cancer that occurs in the small intestine. The study aims to evaluate the effectiveness of different chemotherapy treatments following surgery. The treatments being tested include a regimen of fluoropyrimidine alone and a combination of fluoropyrimidine with Oxaliplatin. These medications are used to help prevent the cancer from returning after it has been surgically removed.

The trial will compare the outcomes of patients who receive chemotherapy with those who are simply observed after surgery. Participants will be randomly assigned to one of these groups. The study will last for 24 weeks, during which patients will receive their assigned treatment. The goal is to determine which approach is more effective in preventing the recurrence of cancer and improving overall survival rates.

Throughout the study, patients will be monitored for any side effects and their overall health will be assessed. The trial will also gather information on the characteristics of the cancer and how it responds to treatment. This research is part of a larger global effort to improve treatment options for small bowel adenocarcinoma and to better understand the disease. The findings from this study could help guide future treatment decisions for patients with this type of cancer.

]]> Study on the Effectiveness of FOLFIRINOX and FOLFOX for Patients with Advanced Small Bowel Cancer Using Calcium Levofolinate, Irinotecan, and Oxaliplatin https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-folfirinox-and-folfox-for-patients-with-advanced-small-bowel-cancer-using-calcium-levofolinate-irinotecan-and-oxaliplatin/ Wed, 29 Apr 2026 14:26:44 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-folfirinox-and-folfox-for-patients-with-advanced-small-bowel-cancer-using-calcium-levofolinate-irinotecan-and-oxaliplatin/ This clinical trial is focused on studying a type of cancer called small bowel adenocarcinoma, which affects the small intestine. The study is evaluating two different treatment combinations for this cancer: modified FOLFIRINOX and FOLFOX. These treatments involve a combination of chemotherapy drugs, including irinotecan hydrochloride trihydrate, oxaliplatin, fluorouracil, and calcium levofolinate. Chemotherapy is a type of cancer treatment that uses drugs to destroy cancer cells.

The purpose of the study is to assess how well these treatments work in patients with locally advanced or metastatic small bowel adenocarcinoma, meaning the cancer has spread or cannot be removed by surgery. The study will look at the percentage of patients who are alive without their cancer getting worse after eight months. Participants will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will last for a period of up to 36 months, during which patients will be monitored regularly to track their progress and any side effects they may experience.

In addition to the main goal of the study, researchers will also look at overall survival rates and how long patients live without their cancer progressing. This information will help determine the effectiveness of the treatments and provide valuable insights into managing small bowel adenocarcinoma. Participants in the study may receive either the treatment or a placebo, which is a substance with no active medication, to compare the results. The findings from this study could lead to improved treatment options for patients with this type of cancer in the future.

]]> Study on the Effectiveness of Chemotherapy with Fluorouracil, Capecitabine, and Oxaliplatin for Patients with Small Bowel Adenocarcinoma https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-chemotherapy-with-fluorouracil-capecitabine-and-oxaliplatin-for-patients-with-small-bowel-adenocarcinoma/ Wed, 29 Apr 2026 14:22:55 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-chemotherapy-with-fluorouracil-capecitabine-and-oxaliplatin-for-patients-with-small-bowel-adenocarcinoma/ This clinical trial is focused on studying the effects of adjuvant chemotherapy in patients with small bowel adenocarcinoma, a type of cancer that occurs in the small intestine. The study will evaluate the benefits of using chemotherapy after surgical removal of the cancer. The medications being tested include Folinic Acid, Capecitabine, Fluorouracil, and Oxaliplatin. These drugs are commonly used in cancer treatment and will be administered in different combinations to see which is most effective.

The purpose of the study is to determine how well these chemotherapy treatments work compared to just observing patients after surgery. Participants will receive either 12 cycles of chemotherapy or 8 cycles if Capecitabine is used. The study will also compare the effectiveness of using Fluorouracil or Capecitabine alone versus in combination with Oxaliplatin. The trial will last for a period of up to 6 months, during which the patients’ health and response to the treatment will be closely monitored.

Throughout the study, the main focus will be on disease-free survival, which means the time patients remain free from cancer after treatment. Other aspects such as overall survival, side effects of the chemotherapy, and quality of life will also be assessed. The study aims to provide valuable information on the best treatment approach for patients with small bowel adenocarcinoma following surgery.

]]>